What is the Role of Antimicrobial Stewardship in Improving Outcomes of Patients with CAP?

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 211-228

  Nussenblatt, Veronique ^a   Avdic, Edina ^b   Cosgrove, Sara ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Antimicrobial stewardship; CAP; Community acquired pneumonia; Outcomes

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFAMANDOLE; CEFUROXIME; CHLORAMPHENICOL; CLARITHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; PLACEBO; PROCAINE PENICILLIN; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC STEWARDSHIP; ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HORMONE BLOOD LEVEL; HUMAN; INTERVENTION STUDY; LENGTH OF STAY; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHLEBITIS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; GUIDELINE ADHERENCE; HUMANS; PNEUMONIA; PRACTICE GUIDELINES AS TOPIC;

EID: 84873538809     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.008     Document Type: Review

References (67)

1. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
2. Buie V.C., Owings M.F., DeFrances C.J., et al. National hospital discharge survey: 2006 summary. National Center for Health Statistics. Vital Health Stat 2010, 13:168.
3. Bonafede M.M., Suaya J.A., Wilson K.L., et al. Incidence and cost of CAP in a large working-age population. Am J Manag Care 2012, 18:380-387.
4. McCabe C., Kirchner C., Zhang H., et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009, 169:1525-1531.
5. Arnold F.W., LaJoie A.S., Brock G.N., et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: community-acquired pneumonia organization international cohort study results. Arch Intern Med 2009, 169:1515-1524.
6. Fakih M.G., Hilu R.C., Savoy-Moore R.T., et al. Do resident physicians use antibiotics appropriately in treating upper respiratory infections? A survey of 11 programs. Clin Infect Dis 2003, 37:853-856.
7. Fok M.C., Kanji Z., Mainra R., et al. Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital. Can Respir J 2002, 9:247-252.
8. Schouten J.A., Hulscher M.E., Kullberg B.J., et al. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors. J Antimicrob Chemother 2005, 56:575-582.
9. Kanwar M., Brar N., Khatib R., et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007, 131:1865-1869.
10. Kuyvenhoven M.M., van Balen F.A., Verheij T.J. Outpatient antibiotic prescriptions from 1992 to 2001 in the Netherlands. J Antimicrob Chemother 2003, 52:675-678.
11. Roumie C.L., Halasa N.B., Grijalva C.G., et al. Trends in antibiotic prescribing for adults in the United States-1995 to 2002. J Gen Intern Med 2005, 20:697-702.
12. File T.M., Gross P.A. Performance measurement in community-acquired pneumonia: consequences intended and unintended. Clin Infect Dis 2007, 44:942-944.
13. Welker J.A., Huston M., McCue J.D. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008, 168:351-356.
14. Nicks B.A., Manthey D.E., Fitch M.T. The Centers for Medicare and Medicaid services (CMS) community-acquired pneumonia core measures lead to unnecessary antibiotic administration by emergency physicians. Acad Emerg Med 2009, 16:184-187.
15. Polk R.E., Fishman N. Antimicrobial stewardship. Mandell, Douglas and Bennett's principles and practice of infectious disease 2010, 7th edition, Churchill Livingstone, Orlando, Florida, No 1. G.L. Mandell, J.C. Bennett, R. Dolin (Eds.).
16. Weber D.J. Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management. Int J Infect Dis 2006, 10:S17-S24.
17. Sutton D.R., Wicks A.C., Davidson L. One-day treatment for lobar pneumonia. Thorax 1970, 25:241-244.
18. Ree G.H., Davis M. Treatment of lobar pneumonia in Papua New Guinea: short course chemotherapy with penicillin or chloramphenicol. J Infect 1983, 6:29-32.
19. Siegel R.E., Alicea M., Lee A., et al. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther 1999, 6:217-222.
20. el Moussaoui R., de Borgie C.A., van den Broek P., et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006, 332:1355.
21. Schonwald S., Gunjaca M., Kolacny-Babic L., et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990, 25(Suppl A):123-126.
22. Kinasewitz G., Wood R.G. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1991, 10:872-877.
23. Schonwald S., Barsic B., Klinar I., et al. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis 1994, 26:706-710.
24. Rizzato G., Montemurro L., Fraioli P., et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995, 8:398-402.
25. O'Doherty B., Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998, 17:828-833.
26. Rahav G., Fidel J., Gibor Y., et al. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents 2004, 24:181-184.
27. Tellier G., Niederman M.S., Nusrat R., et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004, 54:515-523.
28. D'Ignazio J., Camere M.A., Lewis D.E., et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005, 49:4035-4041.
29. Dunbar L.M., Wunderink R.G., Habib M.P., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003, 37:752-760.
30. File T.M., Mandell L.A., Tillotson G., et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007, 60:112-120.
31. Dimopoulos G., Matthaiou D.K., Karageorgopoulos D.E., et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008, 68:1841-1854.
32. Li J.Z., Winston L.G., Moore D.H., et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007, 120:783-790.
33. Jenkins S.G., Brown S.D., Farrell D.J. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008, 7:1.
34. Ehrhardt A.F., Russo R. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections. Am J Med 2001, 111:30S-35S.
35. Lode H., Borner K., Koeppe P., et al. Azithromycin-review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996, 37(Suppl C):1-8.
36. Ramirez J.A., Cooper A.C., Wiemken T., et al. Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin. BMC Infect Dis 2012, 12:159.
37. Mertz D., Koller M., Haller P., et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother 2009, 64:188-199.
38. Ramirez J.A., Vargas S., Ritter G.W., et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999, 159:2449-2454.
39. Ramirez J.A. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995, 22:219-223.
40. Ramirez J.A., Srinath L., Ahkee S., et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995, 155:1273-1276.
41. Lee R.W., Lindstrom S.T. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 2007, 12:111-116.
42. Ramirez J.A., Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001, 161:848-850.
43. Yaqub A., Khan Z. Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia. Pak J Med Sci 2005, 21:259-266.
44. Castro-Guardiola A., Viejo-Rodriguez A.L., Soler-Simon S., et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001, 111:367-374.
45. Oosterheert J.J., Bonten M.J., Schneider M.M., et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006, 333:1193.
46. Omidvari K., de Boisblanc B.P., Karam G., et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998, 92:1032-1039.
47. Norrby S.R., Petermann W., Willcox P.A., et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998, 30:397-404.
48. Athanassa Z., Makris G., Dimopoulos G., et al. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 2008, 68:2469-2481.
49. Rhew D.C., Tu G.S., Ofman J., et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001, 161:722-727.
50. Muller B., Becker K.L., Schachinger H., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983.
51. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
52. Schuetz P., Christ-Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
53. Albrich W.C., Dusemund F., Bucher B., et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in " Real Life" : an International, Multicenter Poststudy Survey (ProREAL). Arch Intern Med 2012, 172:715-722.
54. Long W., Deng X., Zhang Y., et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011, 16:819-824.
55. Capelastegui A., Espana P.P., Quintana J.M., et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004, 39:955-963.
56. Hauck L.D., Adler L.M., Mulla Z.D. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol 2004, 14:669-675.
57. Marrie T.J. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia. Chemotherapy 2004, 50(Suppl 1):11-15.
58. Blasi F., Lori I., Bulfoni A., et al. Can CAP guideline adherence improve patient outcome in internal medicine departments?. Eur Respir J 2008, 32:902-910.
59. Carratala J., Garcia-Vidal C., Ortega L., et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012, 172:922-928.
60. Schouten J.A., Hulscher M.E., Trap-Liefers J., et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. Clin Infect Dis 2007, 44:931-941.
61. Fine M.J., Stone R.A., Lave J.R., et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med 2003, 115:343-351.
62. Avdic E., Cushinotto L.A., Hughes A.H., et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis 2012, 54:1581-1587.
63. Cockburn J., Gibberd R.W., Reid A.L., et al. Determinants of non-compliance with short term antibiotic regimens. Br Med J (Clin Res Ed) 1987, 295:814-818.
64. Halm E.A., Switzer G.E., Mittman B.S., et al. What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?. J Gen Intern Med 2001, 16:599-605.
65. Peyrani P., Christensen D., LaJoie A.S., et al. Antibiotic therapy of hospitalized patients with community-acquired pneumonia: an international perspective from the CAPO Cohort Study. J Ky Med Assoc 2006, 104:513-517.
66. Engel M.F., Postma D.F., Hulscher M.E., et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 2012, [Epub ahead of print].
67. Schouten J.A., Hulscher M.E., Natsch S., et al. Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Qual Saf Health Care 2007, 16:143-149.